e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

2.687 -0.373 (-12.20%)

Streaming Delayed Price Updated: 9:36 AM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗

July 20, 2022

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022 ↗

July 15, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 15, 2022

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗

June 03, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About Allogene Therapeutics ↗

June 03, 2022

Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 17, 2022

Via Benzinga

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data ↗

May 10, 2022

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

U.S. FDA Grants Orphan-Drug Designation for Allogene's ALLO-605 for multiple myeloma ↗

April 27, 2022

Allogene Therapeutics, Inc. (Nasdaq: ALLO) received Orphan-drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its drug candidate ALLO-605 for the treatment of patients with...

Via Benzinga

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗

April 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

April 21, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from...

Via FinancialNewsMedia

Allogene's Preclinical Data Show Healthy Donor-Derived Allogeneic CAR T Cells Have Better Immune Fitness, Killing Activity ↗

March 23, 2022

Allogene Therapeutics Inc (NASDAQ: ALLO) announced the

Via Benzinga

Recap: Allogene Therapeutics Q4 Earnings ↗

February 23, 2022

Allogene Therapeutics (NASDAQ:ALLO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

Allogene Therapeutics Earnings Preview ↗

February 22, 2022

Allogene Therapeutics (NASDAQ:ALLO) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement....

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

February 16, 2022

On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low...

Via Benzinga

FDA Lifts Clinical Hold On Allogene's CAR-T Trials ↗

January 11, 2022

The FDA has lifted the hold on Cellectis SA's (NASDAQ: CLLS) licensed partner, Allogene Therapeutics Inc (NASDAQ: ALLO) clinical trials. The...

Via Benzinga

Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗

January 10, 2022

Pfizer and Bayer inked deals with several companies in gene-editing.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 20, 2021

Gainers Intra-Cellular Therapies (NASDAQ:ITCI) stock rose 18.79% to $46.52 during Monday's pre-market session. The market value of their outstanding shares is at $3.7...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 13, 2021

Gainers Arena Pharmaceuticals (NASDAQ:ARNA...

Via Benzinga

58 Biggest Movers From Yesterday ↗

December 14, 2021

Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-...

Via Benzinga

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗

December 12, 2021

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...

Via Benzinga

Being First Is Not Enough For Crispr Therapeutics ↗

November 15, 2021

CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.

Via InvestorPlace

Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

ALLO earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors

October 21, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

2 Top Healthcare Stocks That Could Be Bought Out in 2022 ↗

October 16, 2021

These two novel-drug makers could be top takeover targets next year.

Via The Motley Fool

Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review ↗

October 15, 2021

It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields.

Via Investor's Business Daily

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week ↗

October 15, 2021

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Via The Motley Fool

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy